Abstract
Effectiveness of Rituximab in Conjunction with Cyclosporine in Managing Refractory Idiopathic Thrombocytopenia
Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Xiuying, Haikou 570311, China
Correspondence Address:
Lie Lin, Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Xiuying, Haikou 570311, China, E-mail: fxj1319459744@126.com
To evaluate the effectiveness of rituximab in conjunction with cyclosporine in managing refractory idiopathic thrombocytopenia. A retrospective analysis was performed on 210 adult individuals diagnosed with refractory idiopathic thrombocytopenia upon admission to our medical facility in 2022. Subsequently, they were categorized into distinct treatment cohorts: 98 individuals in the control group and 112 individuals in the observation group. Standard treatment protocols were administered to the control group, while the observation group received supplementary low-dose rituximab alongside the standard treatment regimen followed by the control group. The evaluation encompassed pre- and post-treatment efficacy, fluctuations in cluster of differentiate 20+ expression and platelet count, levels of interleukin-18 and tumor necrosis factor alpha in patient serum, adverse reactions, and recurrence of thrombocytopenia. 4 w post-treatment, the observation group yielded remarkably superior outcomes, with a total effective rate of 92.86 %, compared to the control group’s rate of 77.55 % (p<0.05). Moreover, the observation group demonstrated diminished cluster of differentiate 20+ expression levels and elevated platelet counts in peripheral lymphocytes relative to the control group, with notable significance (p<0.05). Subsequent to treatment, the observation group manifested diminished interleukin-18 and tumor necrosis factor alpha levels relative to the control group, with substantial significance (p<0.01). Conversely, no noteworthy contrast in the prevalence of adverse reactions was identified between the two groups (p>0.05). The recurrence rate of thrombocytopenic purpura in the observation group was notably reduced as opposed to the control group, a difference that proved to be substantially significant (p<0.05). The concurrent usage of rituximab and cyclosporine in managing refractory idiopathic thrombocytopenic purpura exhibits marked clinical effectiveness and a commendable safety profile. The integrated treatment strategy holds potential benefits for symptom amelioration, enhancement of platelet levels, and the prevention of disease relapse, indicative of favorable attributes.
Full-Text | PDF
